pharmaphorum7d
Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod
Lucentis was first approved in the US in 2007 ... as well as for Vabysmo (faricimab), a bispecific antibody that also provides less frequent dosing in wet AMD and DME.
Business Wire10d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Lucentis was first approved for wet AMD by the FDA in 2006. Genentech is also developing DutaFabs – the next generation of ...
pharmaphorum7d
Italy starts probe into Lucentis biosimilar delay allegation
It cites an “anticompetitive agreement” in the market for Lucentis active ingredient, the anti-VEGF antibody ranibizumab. Specifically, the ACGM claims that the companies entered into a ...
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Nature15y
Development trends for therapeutic antibody fragments
Antibody fragments have also been developed ... The products—ReoPro, Lucentis and Cimzia—are used as treatments for cardiovascular, ophthalmic and immunological indications, respectively ...
Morningstar10d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Lucentis was first approved for wet AMD by the FDA in 2006. Genentech is also developing DutaFabs – the next generation of bispecific antibodies designed for increased efficacy and durability ...